American-Urology-Association. (2003). AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. The Journal of Urology, 170(2 Pt 1), 530–547. doi:10.1097/01.ju.0000078083.38675.79
Chapple, C. (2004). Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for practicing clinician. BJU International, 94 (5). Retrieved from ebscohost.com
Cindolo, L., Pirozzi, L., Sountoulides, P., Fanizza, C., Romero, M., Castellan, P., Simeone, C. (2015). Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH) – associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urology, 15. Retrieved from ebscohost.com
Jemal, A., Fedewa, S., Ma, J., Siegel, R., Lin, C., Brawley, O., & Ward, E. (2015). Prostate cancer incidence and PSA testing in relation to USPSTS screening recommendations. The Journal of the American Medical Association, 314(19), 2054-2061. doi:10.1001/jama.2015.14905.
Lepor, H. (2004). Evaluating Men with Benign Prostatic Hyperplasia. Reviews in Urology, 6(Suppl 1), S8–S15.
McCance, K. L., & Huether, S. E. (2014). Patholphysiology (7th ed.). St. Louis , Missouri: Elsevier.
NIDDK.nih.gov (2015). Benign Prostatic Hypertrophy. Retrieved from: http://www.niddk.nih.gov/health-information/health-topics/urologic-disease/benign-prostatic-hyperplasia-bph/Pages/facts.aspx#1
Solomon, Michael C. (2015). BPH. Retrieved from http://solomonurology.com/treasurecoast/wp-content/uploads/2014/10/Benign_Prostatic_Hyperplasia-BPH-long-1024×339.jpg